Table 3. Univariate analysis of DSS and RFS.

	DSS			RFS
	HR	95% CI	P	HR	95% CI	P
Age	1.055	1.02–1.08	<0.001	1.056	1.03–1.08	<0.001
Stage (I, II vs III, IV)	4.373	2.55–7.49	<0.001	3.965	2.37–6.62	<0.001
Histology a
Group II vs group I	1.069	0.55–2.067	0.84	1.056	0.56–1.96	0.86
Group III vs group I	2.926	1.58–5.40	<0.001	2.577	1.41–4.69	0.001
CD151	1.816	1.06–3.10	0.02	1.773	1.06–2.96	0.02
CD151 (in ER, PR and HER-2 negative tumours)	2.94	1.50–5.74	<0.001	2.541	1.37–4.71	0.008
HER-2	1.541	0.55–4.26	0.402	1.408	0.51–3.88	0.506
P53	1.283	0.71–2.32	0.409	1.112	0.62–1.99	0.72
ER	0.815	0.38–1.72	0.591	0.851	0.419–1.72	0.655
PR	0.962	0.34–2.66	0.94	0.864	0.31–2.38	0.77

Abbreviations: CI=confidence interval; DSS=disease specific survival; ER=oestrogen receptor; HR=hazard ratio; PR=progesterone receptor; RFS=recurrence free survival.

Univariate analysis of age was performed in a linear manner; therefore, there is no referent variable.

^aUnivariate analysis of histology carried out with endometrioid histology as reference. Significant P-values for CD151 are in bold.